Plain-English translation of NCT05546827 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to treating two rare types of melanoma — melanoma that starts in the nose and sinuses, and melanoma that starts in the rectum. Instead of going straight to surgery, patients receive immunotherapy (medications that help your immune system fight cancer) followed by radiation therapy before their surgery. The goal is to shrink the tumor as much as possible before the surgeon removes it.
These types of melanoma are extremely rare and very difficult to treat. Doctors want to see whether giving this medication and radiation before surgery can reduce the size of the tumor, make surgery safer, and improve outcomes for patients.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will first receive immunotherapy (combination medications given as infusions). Depending on how your tumor responds, you will then receive radiation therapy to the tumor area over several weeks. After that, your surgeon will remove the remaining tumor. Throughout the process, your doctors will monitor how well the treatment is working using imaging and exams. The entire treatment timeline typically takes several months, and you will have regular follow-up visits to check your progress.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
M.D. Anderson Cancer Center
Enrollment target
~40 participants
Started
September 2022
Primary completion
July 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Devarati Mitra, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.